Cancer is the second leading cause of death globally, causing 8.8 million deaths and affecting 14 million new victims each year. While there are many cancer treatments, none poses less threat to the human body than Immunotherapy. The problem with Immunotherapy treatment, however, is that currently, there are only a few drugs that have been developed and approved by the FDA. A major drawback in developing these drugs is that we lack the proper and efficient technology to develop them.

---

 

                               iFDA Dimension: 7 x 2.5 x 1cm

Inverted Floating Droplet Array (iFDA) is a microfluidic based single-cell screening analysis tool that helps research institutions and pharmaceutical companies detect rare and valuable biological variants crucial for cancer immunotherapy drug development. It is designed to provide high-throughput and time efficiency, while maintaining a low cost.

The flowchart above demonstrates how iFDA works. It takes a large population of cells and sorts them singly, then it screens for target cells. Finally, those cells can be further analyzed, studied in depth, and used to mass produce antibodies as drugs.